ENMD-2076 is primarily investigated for its potential in cancer therapy due to its ability to inhibit multiple kinases involved in tumor cell proliferation and angiogenesis. It targets Aurora A kinase, which plays a critical role in mitosis, and vascular endothelial growth factor receptors (VEGFRs), which are key regulators of blood vessel formation in tumors. This dual inhibition makes it a candidate for disrupting both cancer cell division and the development of tumor-supporting vasculature. It has shown activity in preclinical models against various solid tumors and hematological malignancies, including breast, ovarian, and leukemia cancers. Clinical trials have explored its use in advanced solid tumors and multiple myeloma, aiming to leverage its multi-kinase inhibition for improved anti-tumor effects. Due to its mechanism, it may also help overcome resistance seen with more selective kinase inhibitors.